Alcohol Dependency Study: Combining Medication Treatment for Alcoholism
Unknown status
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2005-03-01
The purpose of this study is to learn whether ondansetron and topiramate either alone or in
combination is safe and effective in the treatment of alcohol dependence. This 13 week
out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are
post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will
receive ondansetron and topiramate either alone or in combination or a placebo coupled with
psychotherapy.
Alcohol Dependency Study: Combining Medication Treatment for Alcoholism
Unknown status
Bankole Johnson
Phase 2
2005-03-01
The purpose of this study is to learn whether ondansetron and topiramate either alone or in
combination is safe and effective in the treatment of alcohol dependence. This 13 week
out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are
post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will
receive ondansetron and topiramate either alone or in combination or a placebo coupled with
psychotherapy.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2004-09-01
The primary purpose of this study is to test the effectiveness of topiramate for the
treatment of combined alcohol and cocaine dependence. Topiramate is approved for the
treatment of seizures. It has not been proven to be effective for the treatment of alcohol or
cocaine dependence.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
